A SU011248 Expanded Access Protocol For Systemic Therapy Of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible For Participation In Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248
A SU011248 Expanded Access Protocol For Systemic Therapy Of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible For Participation In Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248
The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC who are ineligible for participation in ongoing SU011248 clinical studies and have the potential to derive clinical benefit from treatment with SU011248 based on the judgment of the investigator.
Given that an Expanded Access study does not meet the definition of a controlled clinical investigation, and as such, is not considered an applicable drug clinical trial per NIH, Basic Results for such studies are not required to be reported. Protocol A6181037 has been identified as an Expanded Access trial, and has been registered to ClinicalTrials.gov, however Basic Results will not be posted.
Inclusion Criteria:
Exclusion Criteria:
Heidelburg, Victoria 3084, Australia
Winnnipeg, Manitoba R2H 2A6, Canada
Bogotá, Cundinamarca 0000, Colombia
Clermont Ferand, 63011, France
Homburg/Saar, 66421, Germany
Hong Hong, Hong Kong, Hong Kong
L'hospitalet Del Llobregat, Barcelona 08907, Spain
Ch-4058 Basel, Switzerland
Ch-4101 Bruderholz, Switzerland
Ch-4410 Liesthal, Switzerland
Taoyun, 333, Taiwan
Caracas, Miranda 1060, Venezuela